Pulse Biosciences (NASDAQ:PLSE) Shares Pass Below 50 Day Moving Average of $12.42

Share on StockTwits

Pulse Biosciences Inc (NASDAQ:PLSE) shares passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $12.42 and traded as low as $12.19. Pulse Biosciences shares last traded at $12.44, with a volume of 2,318 shares traded.

A number of equities research analysts recently weighed in on the stock. BidaskClub upgraded shares of Pulse Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. ValuEngine upgraded shares of Pulse Biosciences from a “hold” rating to a “buy” rating in a report on Monday, March 11th. Finally, HC Wainwright assumed coverage on shares of Pulse Biosciences in a report on Monday, February 25th. They issued a “buy” rating and a $27.00 target price on the stock.

The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.13 and a current ratio of 17.13. The company has a market cap of $252.46 million, a P/E ratio of -5.57 and a beta of 1.88.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Tuesday, April 30th. The company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.05). As a group, analysts expect that Pulse Biosciences Inc will post -2.09 earnings per share for the current year.

Large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its stake in shares of Pulse Biosciences by 7.7% in the third quarter. Bank of New York Mellon Corp now owns 66,284 shares of the company’s stock worth $940,000 after purchasing an additional 4,734 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Pulse Biosciences by 29.9% in the third quarter. Vanguard Group Inc. now owns 334,907 shares of the company’s stock worth $4,752,000 after purchasing an additional 77,157 shares during the last quarter. Rhumbline Advisers bought a new stake in shares of Pulse Biosciences in the fourth quarter worth $159,000. Northern Trust Corp grew its stake in shares of Pulse Biosciences by 10.2% in the fourth quarter. Northern Trust Corp now owns 121,031 shares of the company’s stock worth $1,387,000 after purchasing an additional 11,212 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Pulse Biosciences by 49.5% in the fourth quarter. Geode Capital Management LLC now owns 117,149 shares of the company’s stock worth $1,342,000 after purchasing an additional 38,763 shares during the last quarter. Hedge funds and other institutional investors own 9.09% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Pulse Biosciences (NASDAQ:PLSE) Shares Pass Below 50 Day Moving Average of $12.42” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/4380087/pulse-biosciences-nasdaqplse-shares-pass-below-50-day-moving-average-of-12-42.html.

Pulse Biosciences Company Profile (NASDAQ:PLSE)

Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.

Featured Story: Calculate Your Return on Investment (ROI)

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

China Distance Education  Stock Rating Lowered by Zacks Investment Research
China Distance Education Stock Rating Lowered by Zacks Investment Research
Callon Petroleum  Stock Rating Reaffirmed by Northland Securities
Callon Petroleum Stock Rating Reaffirmed by Northland Securities
Canadian Pacific Railway  Rating Reiterated by Cowen
Canadian Pacific Railway Rating Reiterated by Cowen
CNX Resources  Lowered to “Sell” at Zacks Investment Research
CNX Resources Lowered to “Sell” at Zacks Investment Research
COSTAMARE INC/SH  Stock Rating Upgraded by Zacks Investment Research
COSTAMARE INC/SH Stock Rating Upgraded by Zacks Investment Research
Imperial Capital Lowers Callon Petroleum  Price Target to $11.00
Imperial Capital Lowers Callon Petroleum Price Target to $11.00


© 2006-2019 Ticker Report